Despite the encouraging clinical progress of chemotherapeutic agents in cancer treatment,
innovation and development of new effective anticancer candidates still represents a …

Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets
for anticancer drug discovery and development. To date, five histone deacetylase inhibitors …

Met tyrosine kinase, a receptor for a hepatocyte growth factor (HGF), plays a critical role in
tumor growth, metastasis, and drug resistance. Mitochondria are highly dynamic and …

Abstract c-Met is a prototype member of a subfamily of heterodimeric receptor tyrosine
kinases (RTKs) and is the receptor for hepatocyte growth factor (HGF). Binding of HGF to its …

Certain genetically defined cancers are dependent on a single overactive oncogene for their
proliferation and survival, a phenomenon known as “oncogene addiction”. A new generation …

In murine models, overexpression of the MET receptor transgene induces tumors with
human basal gene expression characteristics supporting MET inhibition as a treatment …

MET is a receptor tyrosine kinase known for its pleiotropic effects in tumorigenesis.
Dysregulations of MET expression and/or signaling have been reported and determined to …

MET is expressed on neuroblastoma cells and may trigger tumor growth, neoangiogenesis
and metastasis. MET upregulation further represents an escape mechanism to various …

Abstract Five novel 1H-pyrrolo [2, 3-b] pyridine or 1H-pyrazolo [3, 4-b] pyridine derivatives,
with a methylene, sulfur, sulfoxide or cyclopropyl group as a linker, were designed …

Savolitinib is a novel small-molecule selective cMet inhibitor. This work characterized its
pharmacokinetics in preclinical phase, established the preclinical relationships between PK …